Launching New Ovarian Cancer Clinical Trial, NCI Aims to Predict Disease Relapse | GenomeWeb

The National Cancer Institute is enrolling 400 women who have been treated for advanced-stage ovarian cancer in a new clinical trial that aims to find biomarkers that can predict ovarian cancer relapses.

If successful, the research could lead to the development of an alternative to an existing test for the disease and its relapse, which some scientists say does not predict relapse well because of its relatively poor sensitivity.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.